ERSPC
European Randomized Study of Screening for Prostate Cancer
N = 182,160
- Population
- Men aged 50-74 years at entry, identified through population registries; predefined core age group of men aged 55-69 years (162,243 men in the 2009 report).
- Design
- Multicentre randomised trial in European countries (seven in the 2009 report, eight in later reports). Men identified through population registries were randomly assigned to be offered PSA-based screening (at an average of once every 4 years in the 2009 report) or to a control group not offered screening. Mortality follow-up was identical in both groups; the predefined core age group was 55-69 years.
- Primary endpoint
- Prostate cancer mortality
- Arms
- Offered screening (experimental): Offered PSA-based screening, at an average of once every 4 years in the 2009 report
- Not offered screening (control): No screening offered
- People
- Schröder FH, ERSPC Investigators
Δ Cumulative incidence of prostate cancer+3.4 points
Show the numbers
| Endpoint | Analysis | Offered screening | Not offered screening | Effect |
|---|---|---|---|---|
| Cumulative incidence of prostate cancerThe 2009 abstract does not say whether this figure covers the predefined core age group (162,243 men aged 55-69) or all men randomisedCumulative incidence of prostate cancer during a median follow-up of 9 years, as reported beside the primary mortality outcome. | primarymedian follow-up 9 yearsSchröder 2009 | 8.2% | 4.8% | Primary mortality outcome in the same report (not representable in this schema because only a rate ratio is given): rate ratio for death from prostate cancer 0.80 (95% CI 0.65-0.98; adjusted P=0.04), absolute risk difference 0.71 deaths per 1000 men. Mortality follow-up ended 31 December 2006. |
| Endpoint | Analysis | Offered screening | Not offered screening | Effect |
|---|---|---|---|---|
| Cumulative incidence of prostate cancerThe 2009 abstract does not say whether this figure covers the predefined core age group (162,243 men aged 55-69) or all men randomisedCumulative incidence of prostate cancer during a median follow-up of 9 years, as reported beside the primary mortality outcome. | primarymedian follow-up 9 yearsSchröder 2009 | 8.2% | 4.8% | Primary mortality outcome in the same report (not representable in this schema because only a rate ratio is given): rate ratio for death from prostate cancer 0.80 (95% CI 0.65-0.98; adjusted P=0.04), absolute risk difference 0.71 deaths per 1000 men. Mortality follow-up ended 31 December 2006. |